COMPANY PROFILE

aTyr Pharma

Explore full profile

ATyr Pharma | Brave Science | Meaningful Medicines

San Diego, United StatesFounded 2005Biotech & Life Sciences

Valuation $48M Market cap · 2026

Revenue $190K Latest reported FY

EBITDA $85M Latest reported FY

Total funding $50–100M Disclosed equity funding

About aTyr Pharma

aTyr Pharma is a biopharmaceutical company focused on discovering and developing innovative therapeutics by harnessing newly discovered pathways in biology. The company primarily serves patients with severe and rare diseases, particularly those related to immune and fibrotic conditions. Operating in the biotechnology and pharmaceutical market, aTyr Pharma's business model revolves around research and development of first-in-class therapies, with a significant focus on their lead product candidate, Efzofitimod (ATYR1923), which is currently in Phase 3 clinical trials for pulmonary sarcoidosis. Revenue generation is primarily through partnerships, grants, and potential future product sales upon regulatory approval. Keywords: biopharmaceutical, therapeutics, novel biology, immune diseases, fibrotic conditions, Efzofitimod, pulmonary sarcoidosis, clinical trials, research, development.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2005
Headquarters: San Diego, United States
Listing: IPO 2015
Employees: 75
Open positions: None listed
Dealroom signal: 33.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2c
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning aTyr Pharma.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITY✓Other financing	Mar 2026	$0	—	Undisclosed	↗
POST IPO EQUITY✓Other financing	Feb 2023	$50M	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$190K	0%	$85M	44829.5%	$71M	37447.9%	$42M
2025	$190K	-19.1%	$85M	44829.5%	$71M	37447.9%	$42M
2024	$235K	-33.4%	−$67M	-28600%	−$64M	-27242.6%	$42M
2023	$353K	-96.6%	−$52M	-14781.3%			$42M
2022	$10M	-0.7%	−$46M	-446.8%
2021	$10M	0%	−$34M	-325.3%
2020	$10M	—	−$16M	-152.2%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

aTyr Pharma website traffic

Latest recorded traffic for aTyr Pharma is 6.9K monthly website visits, down 11.5% over the last three months. aTyr Pharma's team declined 6.3% over the past year.

Latest monthly visits6.9K 3-month web change-11.5% 1-year team growth-6.3%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EPEpiPawsOffering DNA testing for pets in order to estimate their age	Fort Lauderdale, United States	Operational	12	$25K	—
TPTME PharmaDeveloping novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME)	Berlin, Germany	Operational
HAHaiiDeveloping innovative digital therapeutics in the prevention and management of mental health and disease such as dementia, depression, and anxiety disorders	Seoul, South Korea	Operational
REResBioticMobilizing an ecosystem of support for the world inside the lungs	Birmingham, United States	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
GAGLX AnalytixBringing personalized medicine to your health care	Copenhagen, Denmark	Operational
RBRevolo BiotherapeuticsDeveloping revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases	Gaithersburg, United States	Operational
RERe-VanaTo advance the quality of care for patients suffering from sight-threatening diseases.	Belfast, United Kingdom	Operational